Jan-Willem C Alffenaar1,2,3,4, Erwin M Jongedijk4, Claudia A J van Winkel4, Margaretha Sariko5, Scott K Heysell6, Stellah Mpagama5, Daan J Touw4. 1. University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia. 2. Westmead Hospital, Sydney, Australia. 3. Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia. 4. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands. 5. Kibong'oto Infectious Diseases Hospital, Kilimanjaro, Tanzania. 6. University of Virginia, Division of Infectious Diseases and International Health, Charlottesville, VA, USA.
Abstract
INTRODUCTION: Therapeutic drug monitoring (TDM) for personalized dosing of fluoroquinolones has been recommended to optimize efficacy and reduce acquired drug resistance in the treatment of MDR TB. Therefore, the aim of this study was to develop a simple, low-cost, robust assay for TDM using mobile UV/visible light (UV/VIS) spectrophotometry to quantify levofloxacin in human saliva at the point of care for TB endemic settings. METHODS: All experiments were performed on a mobile UV/VIS spectrophotometer. The levofloxacin concentration was quantified by using the amplitude of the second-order spectrum between 300 and 400 nm of seven calibrators. The concentration of spiked samples was calculated from the spectrum amplitude using linear regression. The method was validated for selectivity, specificity, linearity, accuracy and precision. Drugs frequently co-administered were tested for interference. RESULTS: The calibration curve was linear over a range of 2.5-50.0 mg/L for levofloxacin, with a correlation coefficient of 0.997. Calculated accuracy ranged from -5.2% to 2.4%. Overall precision ranged from 2.1% to 16.1%. Application of the Savitsky-Golay method reduced the effect of interferents on the quantitation of levofloxacin. Although rifampicin and pyrazinamide showed analytical interference at the lower limit of quantitation of levofloxacin concentrations, this interference had no implication on decisions regarding the levofloxacin dose. CONCLUSIONS: A simple UV/VIS spectrophotometric method to quantify levofloxacin in saliva using a mobile nanophotometer has been validated. This method can be evaluated in programmatic settings to identify patients with low levofloxacin drug exposure to trigger personalized dose adjustment.
INTRODUCTION: Therapeutic drug monitoring (TDM) for personalized dosing of fluoroquinolones has been recommended to optimize efficacy and reduce acquired drug resistance in the treatment of MDR TB. Therefore, the aim of this study was to develop a simple, low-cost, robust assay for TDM using mobile UV/visible light (UV/VIS) spectrophotometry to quantify levofloxacin in human saliva at the point of care for TB endemic settings. METHODS: All experiments were performed on a mobile UV/VIS spectrophotometer. The levofloxacin concentration was quantified by using the amplitude of the second-order spectrum between 300 and 400 nm of seven calibrators. The concentration of spiked samples was calculated from the spectrum amplitude using linear regression. The method was validated for selectivity, specificity, linearity, accuracy and precision. Drugs frequently co-administered were tested for interference. RESULTS: The calibration curve was linear over a range of 2.5-50.0 mg/L for levofloxacin, with a correlation coefficient of 0.997. Calculated accuracy ranged from -5.2% to 2.4%. Overall precision ranged from 2.1% to 16.1%. Application of the Savitsky-Golay method reduced the effect of interferents on the quantitation of levofloxacin. Although rifampicin and pyrazinamide showed analytical interference at the lower limit of quantitation of levofloxacin concentrations, this interference had no implication on decisions regarding the levofloxacin dose. CONCLUSIONS: A simple UV/VIS spectrophotometric method to quantify levofloxacin in saliva using a mobile nanophotometer has been validated. This method can be evaluated in programmatic settings to identify patients with low levofloxacin drug exposure to trigger personalized dose adjustment.
Authors: Simone H J van den Elsen; Tridia van der Laan; Onno W Akkerman; Adri G M van der Zanden; Jan-Willem C Alffenaar; Dick van Soolingen Journal: J Clin Microbiol Date: 2017-08-09 Impact factor: 5.948
Authors: Simone H J van den Elsen; Onno W Akkerman; Erwin M Jongedijk; Mireille Wessels; Samiksha Ghimire; Tjip S van der Werf; Daan J Touw; Mathieu S Bolhuis; Jan-Willem C Alffenaar Journal: Eur Respir J Date: 2020-05-07 Impact factor: 16.671
Authors: Isaac Zentner; Chawangwa Modongo; Nicola M Zetola; Jotam G Pasipanodya; Shashikant Srivastava; Scott K Heysell; Stellah Mpagama; Hans P Schlect; Tawanda Gumbo; Gregory P Bisson; Christopher Vinnard Journal: Int J Infect Dis Date: 2017-12-15 Impact factor: 3.623
Authors: Samiksha Ghimire; Natasha Van't Boveneind-Vrubleuskaya; Onno W Akkerman; Wiel C M de Lange; Dick van Soolingen; Jos G W Kosterink; Tjip S van der Werf; Bob Wilffert; Daniel J Touw; Jan-Willem C Alffenaar Journal: J Antimicrob Chemother Date: 2016-05-26 Impact factor: 5.790
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: J Peter Cegielski; Tracy Dalton; Martin Yagui; Wanpen Wattanaamornkiet; Grigory V Volchenkov; Laura E Via; Martie Van Der Walt; Thelma Tupasi; Sarah E Smith; Ronel Odendaal; Vaira Leimane; Charlotte Kvasnovsky; Tatiana Kuznetsova; Ekaterina Kurbatova; Tiina Kummik; Liga Kuksa; Kai Kliiman; Elena V Kiryanova; HeeJin Kim; Chang-ki Kim; Boris Y Kazennyy; Ruwen Jou; Wei-Lun Huang; Julia Ershova; Vladislav V Erokhin; Lois Diem; Carmen Contreras; Sang Nae Cho; Larisa N Chernousova; Michael P Chen; Janice Campos Caoili; Jaime Bayona; Somsak Akksilp Journal: Clin Infect Dis Date: 2014-07-23 Impact factor: 9.079
Authors: Mohammad H Al-Shaer; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; J Peter Cegielski; Russell R Kempker; Scott K Heysell; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191
Authors: O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-07-01 Impact factor: 3.427
Authors: Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar Journal: Ther Drug Monit Date: 2022-02-01 Impact factor: 3.118
Authors: J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427